United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

amgen ltd - pegfilgrastim - solution for injection - 10mg/1ml

European Union - English - EMA (European Medicines Agency)

accord healthcare s.l.u. - pegfilgrastim - neutropenia - immunostimulants, - reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

Singapore - English - HSA (Health Sciences Authority)

amgen biotechnology singapore pte ltd - pegfilgrastim - injection, solution - 6mg - pegfilgrastim 6mg/0.6ml

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

cipla malaysia sdn bhd - pegfilgrastim -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

accord healthcare sdn.bhd. - pegfilgrastim -

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - pegfilgrastim (unii: 3a58010674) (pegfilgrastim - unii:3a58010674) - stimufend is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia [see clinical studies (14.1)] . limitations of use stimufend is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. stimufend is indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation [see dosage and administration (2.2) and clinical studies (14.2)]. stimufend is contraindicated in patients with a history of serious allergic reactions to pegfilgrastim products or filgrastim products. reactions have included anaphylaxis [see warnings and precautions (5.3)] . risk summary although available data with stimufend or pegfilgrastim product use in pregnant women are insufficient to establish whether there is a drug associated risk of major birth defects,

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - pegfilgrastim 10 mg/ml - solution for injection - 10 mg/ml - active: pegfilgrastim 10 mg/ml excipient: glacial acetic acid polysorbate 20 sodium hydroxide sorbitol water for injection - reduction in the duration of neutropenia, the incidence of febrile neutropenia and the incidence of infection as manifested by febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - pegfilgrastim 10 mg/ml - solution for injection - 6 mg/0.6ml - active: pegfilgrastim 10 mg/ml excipient: acetic acid polysorbate 20 sodium hydroxide sorbitol water for injection - ziextenzo is indicated for the reduction in the duration of neutropenia, the incidence of febrile neutropenia and the incidence of infection as manifested by febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

amgen manufacturing limited - pegfilgrastim - pegfilgrastim....6.0 mg.

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

sandoz gmbh - pegfilgrastim - pegfilgrastim....6.0 mg